Integra LifeSciences executive Robert T. Davis Jr., EVP & President, TT, received a grant of 43,350 restricted stock units on March 11, 2026. These RSUs vest 33% on the first and second anniversaries and 34% on the third anniversary of the grant date.
To cover tax obligations, 8,487 shares of common stock were disposed of at $9.61 per share on March 11, 2026, and 687 shares at $9.55 per share on March 10, 2026, both classified as tax-withholding transactions rather than open-market sales. After these transactions, Davis directly holds 66,387 shares of common stock and 43,350 RSUs.
INTEGRA LIFESCIENCES HOLDINGS CORP senior vice president and principal accounting officer Jeffrey Mosebrook received a grant of 15,957 restricted stock units on March 11, 2026. These RSUs will vest 33% on the first and second anniversaries of the grant date and 34% on the third anniversary.
To cover tax liabilities, 341 common shares at $9.55 per share on March 10, 2026 and 806 common shares at $9.61 per share on March 11, 2026 were withheld. Following these transactions, Mosebrook directly owns 35,453 common shares and holds 15,957 RSUs.
INTEGRA LIFESCIENCES HOLDINGS CORP EVP & Chief Financial Officer Lea Daniels Knight reported a compensation-related equity grant and routine tax withholding. She received 111,179 restricted stock units linked to common stock, which vest 33% on the first and second anniversaries of the March 11, 2026 grant date and 34% on the third anniversary.
On the same date, 8,089 shares of common stock were disposed of at $9.61 per share to cover tax obligations, and she now directly holds 50,489 common shares.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Chantal Veillon-Berteloot, EVP & CHRO, reported an equity compensation grant and related tax withholding. She received 41,783 restricted stock units, each representing one share of common stock. The award will vest 33% on the first and second anniversaries and 34% on the third anniversary of the 3/11/2026 grant date.
On the same date, 5,420 shares of common stock were disposed of at $9.61 per share to satisfy tax liabilities through share withholding, rather than an open-market sale. Following these transactions, Veillon-Berteloot directly owns 22,227 shares of common stock.
Poul Mojdeh reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP reported that President & CEO Poul Mojdeh received a grant of 343,393 restricted stock units tied to common stock. The award vests in three equal annual installments on the first, second, and third anniversaries of the March 11, 2026 grant date.
The units are structured as deferred compensation, to be delivered within 30 days after the first business day following six months after her separation of service. Vesting may accelerate if employment ends due to death, disability, or a qualifying termination within 24 months after a change in control. Following this grant, her reported holdings in this RSU award total 445,691 units.
Hutchinson Michael Damon reported acquisition or exercise transactions in this Form 4 filing.
INTEGRA LIFESCIENCES HOLDINGS CORP executive Michael Damon Hutchinson, EVP and Chief Legal Officer, received a grant of 70,305 restricted stock units tied to common stock. This award will vest 33% on the first and second anniversaries and 34% on the third anniversary of the March 11, 2026 grant date, increasing his directly held RSU position to 159,911 units.
Integra LifeSciences Holdings Corporation filed a shelf registration on Form S-3 registering common stock, preferred stock, debt securities, warrants, purchase contracts and units for possible future offers. The prospectus permits offers "from time to time after the effective date" and states supplements will disclose specific amounts, prices and terms.
The company notes its common stock trades on Nasdaq under the symbol IART and cites a closing price of $11.59 per share on February 25, 2026. The filing also discloses that as of December 31, 2025 there were 77,886,634 shares of common stock issued and 14,398,724 shares designated as treasury stock.
Integra LifeSciences Holdings Corporation files its Annual Report describing a global medical technology business focused on neurosurgery, surgical instruments, ENT and regenerative tissue products. The Codman Specialty Surgical segment provides about 70% of revenue, with Tissue Technologies contributing about 30%.
The company highlights its leadership in neurosurgery, advanced wound care and soft-tissue reconstruction, supported by a broad R&D program and global sales network. It is pursuing PMA approvals for SurgiMend and DuraSorb in breast reconstruction, targeted for 2026, and is relocating and expanding manufacturing capacity, including a new Braintree, Massachusetts facility.
Integra outlines extensive quality and regulatory initiatives, including a Compliance Master Plan to upgrade its quality management systems and respond to FDA expectations. The report also details competitive dynamics, reimbursement and healthcare reform pressures, and comprehensive global regulatory and data privacy obligations. As of June 30, 2025, non‑affiliate market value was about $925.1 million, with 77,937,208 common shares outstanding as of February 25, 2026.
Integra LifeSciences reported flat-to-modest growth in 2025 but a large GAAP loss driven by non-cash charges. Full-year revenue was $1,635.2 million, up 1.5%, while GAAP earnings per diluted share fell to $(6.74) from $(0.09), mainly due to a $511 million goodwill impairment recorded in the second quarter.
On an adjusted basis, 2025 EBITDA was $317.5 million (19.4% margin), slightly below 2024, and adjusted earnings per diluted share declined to $2.23 from $2.56. Free cash flow for the year was negative at $(31.1) million, and net debt stood at $1.60 billion with a total leverage ratio of 4.5x and liquidity of about $516 million.
In the fourth quarter, revenue was $434.9 million, down 1.7%, with organic revenue down 2.5%. GAAP EPS was $(0.02), and adjusted EPS was $0.83. For 2026, the company guides revenue to $1,662–$1,702 million and adjusted EPS to $2.30–$2.40, with Q1 revenue of $375–$390 million and adjusted EPS of $0.37–$0.45.
Integra LifeSciences Holdings Corp received an amended ownership report from institutional investor Fuller & Thaler Asset Management, Inc. as of 12/31/2025. Fuller & Thaler reports beneficial ownership of 3,636,359.96 shares of Integra common stock, representing 4.67% of the class.
The firm has sole power to vote 3,583,652.96 shares and sole power to dispose of 3,636,359.96 shares, with no shared voting or dispositive power. Fuller & Thaler certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Integra.